We developed a highly potent anticancer
agent, dolastatinol, which
is a methylene hydroxyl derivative of dolastatin 10. Dolastatinol
is a synthetic analog of dolastatin 10, synthesized by a solid-phase
peptide Fmoc chemistry protocol on 2-chlorotrityl chloride resin utilizing
a pH-triggering self-immolative monosuccinate linker. The introduction
of the C-terminus hydroxyl methylene functionality preserves the anticancer
properties of the parent dolastatin 10, including strong suppression
of the cell proliferation, migration, high cytotoxicity. Our research
establishes a new facile route toward the further development of C-terminus-modified
dolastatin-10-based microtubule inhibitors for anticancer treatment.